These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 17442465

  • 21. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
    Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ.
    Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
    [Abstract] [Full Text] [Related]

  • 22. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.
    Al-Mariri A.
    Vaccine; 2010 Feb 17; 28(7):1766-70. PubMed ID: 20036752
    [Abstract] [Full Text] [Related]

  • 23. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
    Li ZQ, Shi JX, Fu WD, Zhang Y, Zhang J, Wang Z, Li TS, Chen CF, Guo F, Zhang H.
    Mol Immunol; 2015 Aug 17; 66(2):276-83. PubMed ID: 25899866
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination.
    Guilloteau LA, Laroucau K, Olivier M, Grillo MJ, Marin CM, Verger JM, Blasco JM.
    Vaccine; 2006 Apr 24; 24(17):3461-8. PubMed ID: 16519974
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice.
    Clausse M, Díaz AG, Ibañez AE, Cassataro J, Giambartolomei GH, Estein SM.
    Clin Vaccine Immunol; 2014 Dec 24; 21(12):1689-94. PubMed ID: 25339409
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
    Al-Mariri A, Abbady AQ.
    J Infect Dev Ctries; 2013 Apr 17; 7(4):329-37. PubMed ID: 23592643
    [Abstract] [Full Text] [Related]

  • 28. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis.
    Pasquevich KA, García Samartino C, Coria LM, Estein SM, Zwerdling A, Ibañez AE, Barrionuevo P, Oliveira FS, Carvalho NB, Borkowski J, Oliveira SC, Warzecha H, Giambartolomei GH, Cassataro J.
    J Immunol; 2010 May 01; 184(9):5200-12. PubMed ID: 20351187
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against Brucella melitensis infection.
    Abkar M, Fasihi-Ramandi M, Kooshki H, Sahebghadam Lotfi A.
    Int J Nanomedicine; 2017 May 01; 12():8769-8778. PubMed ID: 29263667
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection.
    Ghasemi A, Jeddi-Tehrani M, Mautner J, Salari MH, Zarnani AH.
    Vaccine; 2015 Oct 13; 33(42):5532-5538. PubMed ID: 26384448
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
    Yang X, Walters N, Robison A, Trunkle T, Pascual DW.
    Vaccine; 2007 Mar 08; 25(12):2261-8. PubMed ID: 17239499
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams.
    Da Costa Martins R, Irache JM, Blasco JM, Muñoz MP, Marín CM, Jesús Grilló M, Jesús De Miguel M, Barberán M, Gamazo C.
    Vaccine; 2010 Apr 09; 28(17):3038-46. PubMed ID: 19887131
    [Abstract] [Full Text] [Related]

  • 37. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
    Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG.
    Vet Microbiol; 2004 Sep 08; 102(3-4):237-45. PubMed ID: 15327798
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A comparison between adjuvant and delivering functions of calcium phosphate, aluminum hydroxide and chitosan nanoparticles, using a model protein of Brucella melitensis Omp31.
    Abkar M, Alamian S, Sattarahmady N.
    Immunol Lett; 2019 Mar 08; 207():28-35. PubMed ID: 30707922
    [Abstract] [Full Text] [Related]

  • 40. Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection.
    Sancho P, Tejedor C, Sidhu-Muñoz RS, Fernández-Lago L, Vizcaíno N.
    Vet Res; 2014 Jun 04; 45(1):61. PubMed ID: 24898325
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.